Novo Nordisk (NOVOB.DK) shares are gaining 3.0% after the company raised its sales forecast for 2023 on strong demand for Ozempic and Wegovy medicines.
- Operating profit at constant exchange rates +40% to +46%, previously expected +31% to +37%, Bloomberg estimated +37.5%
- Sales at constant exchange rates +32% to +38%, previously expected +27% to +33%, Bloomberg estimated +31.7%.
Daily Summary: A grim end to a difficult week
Without Jensen: Markets at the Mercy of the Fed
US OPEN: Selling pressure eases, Anthropic gives back post-IPO gains
Market Wrap: Global stocks post 7th consecutive session of losses, Anthropic failed to reassure the market (20.11.2026)